Gilead Sciences

VEKLURY

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Gilead Sciences

Veklury HCPCS:

J0248

HCPCS Code Descriptor:

Injection, remdesivir, 1 mg

Category:

J Code

Veklury NDCs:

61958-2902-01, 61958-2901-02, 61958-2901-01

Primary Type:

COVID-19

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Veklury CPT Codes:

-96365 - Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

-96366 - Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (list separately in addition to code for primary procedure)

-96367 -Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (list separately in addition to code for primary procedure)

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have identified listing errors with the following NDCs:

61958-2901-01, 61958-2902-01

About Veklury:

VEKLURY is a COVID-19 drug manufactured by Gilead Sciences and administered via the Intravenous route of administration. The J Code: J0248 is aligned to the drug VEKLURY.

ACCESS PRICING AND MORE BY REGISTERING

J0248 Added Date:

December 23, 2021

J0248 Effective Date:

December 23, 2021

J0248 Termination Date:

HCPCS Active

Veklury billing and coding information can be found through Gilead Sciences at the link below:
Our team did not identify a source for Veklury patient assistance information. Please reach out to our team if you feel that this is a mistake.
VEKLURY prescribing information can be found at the link below:
Information regarding VEKLURY’s side effects can be found at MedlinePlus